| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 1
| Issue : 1 | Page : 35-39 |
|
|
Clinical outcomes of switching antiplatelet therapy from prasugrel to clopidogrel after 3–6 months of percutaneous coronary intervention with drug-eluting stents: A preliminary study
Shaheda Siddiqui1, Gurrala Rajashekar Reddy2, Hafsa Sania1, Hafsah Hani1, Maryam Shoukath1, Madiha Nooreen1, Vinod K Unni2, Parvaiz Kadloor1
1 Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, India
2 Department of Cardiology, Deccan College of Medical Sciences, Hyderabad, India
Correspondence Address:
Dr. Shaheda Siddiqui
Assistant Professor, Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/IHJI.IHJI_12_17
|
|
|
Introduction: Dual antiplatelet therapy comprising aspirin and a P2Y12-receptor inhibitor for 1 year is the recommended treatment for the prevention of recurrent thrombotic events in patients who have undergone percutaneous coronary intervention (PCI) with the implantation of drug-eluting stent (DES). Objectives: To assess the safety and efficacy of switching the subjects from prasugrel to clopidogrel after 3–6 months of PCI with DES. Materials and methods: It is a single-center, prospective study conducted in a tertiary care hospital. The study included 100 subjects who underwent PCI with DES using prasugrel as the initial antiplatelet agent along with aspirin. Between 3 and 6 months after PCI, the patients were switched from prasugrel to clopidogrel without a loading dose. These subjects were followed up at day 28 and day 90 after switch for adverse events. Results: The mean age of subjects was 52.58±10.14 years. Of the total subjects, 59% were male and 41% were female. Approximately 53% subjects were switched after 3 months of PCI, whereas 47% were switched after 6 months. At day 28 and day 90 after switch, no major adverse cardiovascular events (including stent thrombosis) were reported. Only two episodes of minor bleeding were observed between day 28 and day 90. Conclusion: In this preliminary study, no major events, ischemic or bleeding, during the follow-up period after the subjects were switched from prasugrel to clopidogrel were reported. These findings suggest that switching the subjects from prasugrel to clopidogrel after 3–6 months of PCI may be safe and effective.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
